ArticleDrug design, development and therapy2018
HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment.
Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Experimental evaluation of Nilotinib and Paclitaxel co-delivered via albumin nanoparticles as a therapeutic strategy for lung squamous cell carcinoma.Clinical and experimental medicine · 2026Article
- Sorafenib nanoparticles coated with Eudragit RL for ocular drug delivery: a potential treatment for diabetic retinopathy.International journal of pharmaceutics: X · 2026Article
- Preparation of human serum albumin-doxorubicin modified carbon nanotubes mediated combined photothermal and chemotherapeutic strategies in melanoma application.Journal of materials science. Materials in medicine · 2025Article
- Albumin as a natural and moldable biomaterial for biomimetic drug delivery applications.International journal of pharmaceutics · 2025Review
- Investigation of bioavailability and anti-pancreatic cancer efficacy of a self-nanoemulsifying erlotinib delivery system.Therapeutic delivery · 2025Article
- Wolf in Sheep's Clothing: Taming Cancer's Resistance with Human Serum Albumin?International journal of nanomedicine · 2025Review
- Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors.Asian journal of pharmaceutical sciences · 2024Review
- Hyaluronic Acid Nanoparticles with Parameters Required forBiomacromolecules · 2024Article
- Use of Albumin for Drug Delivery as a Diagnostic and Therapeutic Tool.Current pharmaceutical biotechnology · 2024Review
- Albumin Nanoparticle-Based Drug Delivery Systems.International journal of nanomedicine · 2024Review
- The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer.Biomedicines · 2023Review
- Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges.Polymers · 2023Review
- Novel Development of Nanoparticles-A Promising Direction for Precise Tumor Management.Pharmaceutics · 2022Review
- Review targeted drug delivery systems for norcantharidin in cancer therapy.Journal of nanobiotechnology · 2022Review
- On-demand assembly of polymeric nanoparticles for longer-blood-circulation and disassembly in tumor for boosting sonodynamic therapy.Bioactive materials · 2022Article
- Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs.Pharmaceutics · 2022Review
- Chondroitin sulfate conjugation facilitates tumor cell internalization of albumin nanoparticles for brain-targeted delivery of temozolomide via CD44 receptor-mediated targeting.Drug delivery and translational research · 2021Article
- Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?Pharmaceutics · 2021Review
- Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR).Molecules (Basel, Switzerland) · 2021Review
- The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors.Beilstein journal of nanotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAim of this study was to prepare the hyaluronic acid and human serum albumin modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation method.
methodsERT-HSA-HA NPs were characterized for physical properties, such as morphology and particle size, and in vitro drug release. Moreover, the cytotoxicity, cellular uptake, in vivo studies of ERT-HSA-HA nanoparticle were investigated and compared in A549 cells.
resultsThe ERT-HSA-HA NPs showed spherical morphology, and their hydrodynamic diameter was 112.5±2.8 nm. The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively. After 3 months of storage, no dramatic change, such as visible aggregation, drug content changes, and precipitation, in the appearance of ERT-HSA-HA NPs occurred. In vitro release showed that the release of ERT from HSA-HA NPs was slow, without obvious burst effects at an early stage. In in vivo studies, ERT-HSA-HA NPs showed a superior antiproliferative effect on A549 cells, and the HA modification strategy can also facilitate the high-efficiency uptake of ERT-HSA NPs by A549 cells. Pharmacokinetic studies showed that the form of NPs could significantly extend the role of ERT in vivo (provided higher bioavailability). However, there was no significant difference in the pharmacokinetic parameters between ERT-HSA NPs and ERT-HSA-HA NPs after intravenous administration. In terms of in vivo antitumor activity, ERT-HSA-HA NP-treated mice showed a significantly suppressed tumor growth and no relapse after 30 d of treatment.
conclusionHA/HSA co-modified erlotinib albumin nanoparticles was expected to be a new strategy in the treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.